Developer docs
API playgroundTry for free, no card

Search company profiles

Kalocyte

Full company profile

uuid0000ksu

Namestring
Kalocyte
Legal namestring
KaloCyte, Inc.
Websiteurl
kalocyte.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

KaloCyte is a pre-clinical stage biotech company founded in 2016 and headquartered in Baltimore, Maryland, developing ErythroMer, a nano-encapsulated human hemoglobin-based artificial red blood cell substitute. ErythroMer is a freeze-dried powder formulated in a soft lipid nanoparticle shell with the proprietary KC1003 molecule that regulates ATP binding to hemoglobin, enabling oxygen delivery that mimics native red blood cell physiology. The product is designed to be shelf-stable for years at ambient temperatures and reconstituted for transfusion in under two minutes, targeting settings where stored red blood cells are unavailable, undesirable, or in short supply — primarily military and battlefield medicine, civilian EMS and pre-hospital trauma care, and hospitals/trauma centers. The company is built on co-founder IP developed at Washington University in St. Louis (Drs. Doctor, Pan, Spinella) and operates as a University of Maryland BioPark Affiliate with labs sited within UMSOM's Center for Blood Oxygen Transport and Hemostasis (CBOTH).

The business model is currently pre-revenue and is funded through a combination of federal grants (over $19M from DARPA, NIH, and DoD supporting preclinical development, IND-enabling toxicology, and lyophilization optimization) and equity capital (over $8M from investors including Ferocity Capital, TEDCO, New York Blood Center, Maryland Momentum Fund, and others). Major institutional positions include participation in DARPA's $46M FSHARP consortium, Blue Knight selection under the BARDA/Johnson & Johnson Innovation JLABS partnership, and an exclusive 2025 licensing agreement with Chrysea for biosynthetic hemoglobin supply. Pricing for the future commercial product has not been publicly disclosed, but management has stated the intent to price ErythroMer at approximately the fully-loaded cost of a unit of blood, with US market potential estimated at $7 billion. Future distribution will flow through pharmaceutical and medical supply channels to hospitals, EMS providers, and military medical facilities via direct sales and standard medical procurement.

Go-to-market is staged: pre-commercial today, with regulatory de-risking via FDA CBER INTERACT and Pre-IND engagement, planned first-in-human trials following IND submission, and eventual commercialization contingent on FDA approval. The current customer pipeline is concentrated in government/defense (DoD, DARPA, BARDA) for procurement and stockpiling, with civilian hospital and EMS segments representing a longer-tail commercial opportunity.

Short descriptiontext

KaloCyte is a pre-clinical stage biotech developing ErythroMer, a freeze-dried, nano-encapsulated artificial red blood cell substitute for emergency transfusion when stored blood is unavailable. The company targets military medicine, EMS, and hospital trauma markets ahead of FDA approval.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBaltimore, United States
HQ citystring
Baltimore
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
blood substitute therapy, artificial red blood cells, hemoglobin-based oxygen carriers, trauma transfusion products, freeze-dried biopharmaceuticals
Industry1 code
PRIMARYHLAAAAAK
Therapeutic Enzymes & Enzyme Replacement Therapies (ERT)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Blood Substitute Pharmaceuticals
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Grant Funding
TypeLicensing Royalties
Description

Federal grants from DARPA, NIH, and DoD supporting ErythroMer development and preclinical testing.

kalocyte.com
2Investor Funding
TypeLicensing Royalties
Description

Equity investments from venture capital, angel investors, and strategic investors to fund R&D and clinical development.

kalocyte.com
3Pharmaceutical Product Sales (Future)
TypeOne Time License
Description

Once FDA approved, ErythroMer will be commercialized as a pharmaceutical/medical product sold to hospitals, emergency medical services, and military. Market potential estimated at $7 billion in the US alone.

kalocyte.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Kalocyte is a pre-clinical stage biotech company developing ErythroMer, a dried, bio-inspired artificial red blood cell substitute for emergency transfusion. ErythroMer is a nano-encapsulated human hemoglobin in a soft lipid nanoparticle shell that mimics native RBC physiology, can be freeze-dried for long-term ambient storage, and is reconstituted for transfusion in under two minutes. It is designed for use when stored red blood cells are unavailable, undesirable, or in short supply.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Every minute of delay in replacing lost blood increases mortality by 5%
+3 more records
Product overview1 text field

Kalocyte is developing a single core product, ErythroMer, a shelf-stable, dried artificial red blood cell substitute. The company is a pre-clinical stage biotech startup focused on transforming emergency and trauma care by providing a bio-inspired oxygen carrier that addresses the critical need for blood transfusion solutions in settings where stored blood is unavailable, impractical, or in short supply.

Product and service1 record
1ErythroMer
CategoryBlood Substitute Pharmaceuticals
Description

ErythroMer is a dried, bio-inspired artificial red blood cell designed to treat life-threatening blood loss when stored red blood cells are unavailable, undesirable, or in short supply. It is a nano-encapsulated human hemoglobin that mimics natural RBC physiology, can be freeze-dried for long-term storage at ambient conditions, and reconstituted in under two minutes for transfusion.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-01
Description

Exclusive licensing agreement for biosynthetic hemoglobin production. Global partnership combining Chryseas synthetic biology expertise with KaloCytes artificial red blood cell technology for medical emergency care.

2Blue Knight (BARDA/Johnson & Johnson Innovation)
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-01-28
Description

Strategic collaboration between Biomedical Advanced Research and Development Authority (BARDA) and Johnson & Johnson JLABS. Blue Knight supports early-stage innovation in health security technologies. KaloCyte selected as Blue Knight company and awarded $250K QuickFire Challenge.

kalocyte.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-31
Description

Collaboration with UMB researchers led by Dr. Allan Doctor for ErythroMer development. KaloCyte is part of DARPA FSHARP consortium led by UMB School of Medicine. Company is UM BioPark affiliate with labs in UM School of Medicine's Center for Blood Oxygen Transport and Hemostasis (CBOTH).

4University of Maryland BioPark
Strategic tierCoreTypeStrategic or Co-development Partner
Description

KaloCyte is a UM BioPark Affiliate, located at Connect Labs at 4MLK. Provides access to research facilities, startup support resources, and Maryland biotech ecosystem.

kalocyte.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Co-founder Dr. Phil Spinella is Professor at University of Pittsburgh and co-directs Trauma and Transfusion Medicine Research Center. Collaboration on transfusion medicine research and DARPA programs.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Co-founder Dr. Dipanjan Pan is Dorothy Foehr Huck & J. Lloyd Huck Chair Professor in Nanomedicine at Penn State University. Co-invented ErythroMer with UMB team.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Leveraged BioGenerator's Grants, Fundamentals, and Grants-2-Business programs to craft and implement technical differentiation, accelerating regulatory path, and Federal de-risking grants strategies.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Haima Therapeutics is a Cleveland-based pre-clinical biotech developing synthetic and cryopreserved platelet products for trauma and surgical bleeding. It is the closest direct peer to KaloCyte, sharing the DARPA FSHARP consortium and a focus on shelf-stable blood product substitutes for hemorrhage control.

TypeDirect peer
Description

Velico Medical is developing spray-dried plasma and other dried, shelf-stable blood products for pre-hospital and battlefield use. It directly overlaps KaloCyte's mission of fieldable, cold-chain-free transfusion therapeutics and targets the same end customers.

TypeDirect peer
Description

Prolong Pharmaceuticals is developing PEGylated hemoglobin-based oxygen carriers (SANGUINATE) for sickle cell disease and other indications. It is a direct competitor in the hemoglobin-based oxygen carrier (HBOC) therapeutic space that ErythroMer is also pursuing.

4HbO2 Therapeutics
TypeBroad incumbent
Description

HbO2 Therapeutics (a subsidiary of OPKO Health) holds and develops hemoglobin-based oxygen carrier platforms, including the legacy Biopure/Hemopure program. It is a broad incumbent in the HBOC category and competes for the same regulatory and clinical milestones KaloCyte targets.

TypeBroad incumbent
Description

CSL Behring is a global leader in plasma-derived and recombinant blood product therapies. As a broad incumbent in transfusion medicine, it represents both a potential competitor and a likely strategic-acquirer counterpart for KaloCyte's blood substitute franchise.

TypeBroad incumbent
Description

Baxter is a major global manufacturer of blood storage, processing and intravenous fluid products used in transfusion and trauma care. It operates broadly in the same end markets (hospitals, trauma centers, EMS) that KaloCyte plans to serve with ErythroMer.

TypeBroad incumbent
Description

Octapharma is one of the world's largest plasma product manufacturers, producing coagulation factors, immunoglobulins, and blood volume replacement products used in trauma and surgery. It is a broad incumbent serving the same hospital and emergency medicine channels targeted by ErythroMer.

TypeOthers
Description

Cerus develops INTERCEPT pathogen-reduction systems for platelets, plasma, and red blood cells. It is an adjacent enabling technology provider in the transfusion medicine ecosystem rather than a direct blood substitute competitor.

TypeOthers
Description

Terumo BCT manufactures blood collection, processing, and storage devices, and is developing pathogen-reduced and cryopreserved blood products. It is an adjacent supplier/infrastructure peer that supports the broader transfusion ecosystem in which ErythroMer would compete.

TypeOthers
Description

New York Blood Center is both a major blood bank operator and the venture investor that has backed KaloCyte (via NYBC Ventures). It is an ecosystem participant/strategic investor rather than a direct product competitor.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles21 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kalocyte

Blood Substitute Pharmaceuticalskalocyte.com

KaloCyte is a pre-clinical stage biotech developing ErythroMer, a freeze-dried, nano-encapsulated artificial red blood cell substitute for emergency transfusion when stored blood is unavailable. The company targets military medicine, EMS, and hospital trauma markets ahead of FDA approval.

What Kalocyte does

KaloCyte is a pre-clinical stage biotech company founded in 2016 and headquartered in Baltimore, Maryland, developing ErythroMer, a nano-encapsulated human hemoglobin-based artificial red blood cell substitute. ErythroMer is a freeze-dried powder formulated in a soft lipid nanoparticle shell with the proprietary KC1003 molecule that regulates ATP binding to hemoglobin, enabling oxygen delivery that mimics native red blood cell physiology. The product is designed to be shelf-stable for years at ambient temperatures and reconstituted for transfusion in under two minutes, targeting settings where stored red blood cells are unavailable, undesirable, or in short supply — primarily military and battlefield medicine, civilian EMS and pre-hospital trauma care, and hospitals/trauma centers. The company is built on co-founder IP developed at Washington University in St. Louis (Drs. Doctor, Pan, Spinella) and operates as a University of Maryland BioPark Affiliate with labs sited within UMSOM's Center for Blood Oxygen Transport and Hemostasis (CBOTH).

The business model is currently pre-revenue and is funded through a combination of federal grants (over $19M from DARPA, NIH, and DoD supporting preclinical development, IND-enabling toxicology, and lyophilization optimization) and equity capital (over $8M from investors including Ferocity Capital, TEDCO, New York Blood Center, Maryland Momentum Fund, and others). Major institutional positions include participation in DARPA's $46M FSHARP consortium, Blue Knight selection under the BARDA/Johnson & Johnson Innovation JLABS partnership, and an exclusive 2025 licensing agreement with Chrysea for biosynthetic hemoglobin supply. Pricing for the future commercial product has not been publicly disclosed, but management has stated the intent to price ErythroMer at approximately the fully-loaded cost of a unit of blood, with US market potential estimated at $7 billion. Future distribution will flow through pharmaceutical and medical supply channels to hospitals, EMS providers, and military medical facilities via direct sales and standard medical procurement.

Go-to-market is staged: pre-commercial today, with regulatory de-risking via FDA CBER INTERACT and Pre-IND engagement, planned first-in-human trials following IND submission, and eventual commercialization contingent on FDA approval. The current customer pipeline is concentrated in government/defense (DoD, DARPA, BARDA) for procurement and stockpiling, with civilian hospital and EMS segments representing a longer-tail commercial opportunity.

Kalocyte firmographics

Firmographics
Name
Kalocyte
Legal name
KaloCyte, Inc.
Website
https://kalocyte.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
KaloCyte is a pre-clinical stage biotech developing ErythroMer, a freeze-dried, nano-encapsulated artificial red blood cell substitute for emergency transfusion when stored blood is unavailable. The company targets military medicine, EMS, and hospital trauma markets ahead of FDA approval.
Ownership category
akta.pro rank

Kalocyte industry classification

Industry
Product category
Blood Substitute Pharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAK
Therapeutic Enzymes & Enzyme Replacement Therapies (ERT)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Blood substitute therapy
  • Artificial red blood cells
  • Hemoglobin-based oxygen carriers
  • Trauma transfusion products
  • Freeze-dried biopharmaceuticals

Where Kalocyte is headquartered

Location

Headquarters

HQ city
Baltimore
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Kalocyte business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain

Revenue model

  1. Grant Funding: Federal grants from DARPA, NIH, and DoD supporting ErythroMer development and preclinical testing.
  2. Investor Funding: Equity investments from venture capital, angel investors, and strategic investors to fund R&D and clinical development.
  3. Pharmaceutical Product Sales (Future): Once FDA approved, ErythroMer will be commercialized as a pharmaceutical/medical product sold to hospitals, emergency medical services, and military. Market potential estimated at $7 billion in the US alone.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Kalocyte product offering

Product offering

Core offering

Kalocyte is a pre-clinical stage biotech company developing ErythroMer, a dried, bio-inspired artificial red blood cell substitute for emergency transfusion. ErythroMer is a nano-encapsulated human hemoglobin in a soft lipid nanoparticle shell that mimics native RBC physiology, can be freeze-dried for long-term ambient storage, and is reconstituted for transfusion in under two minutes. It is designed for use when stored red blood cells are unavailable, undesirable, or in short supply.

Product overview

Kalocyte is developing a single core product, ErythroMer, a shelf-stable, dried artificial red blood cell substitute. The company is a pre-clinical stage biotech startup focused on transforming emergency and trauma care by providing a bio-inspired oxygen carrier that addresses the critical need for blood transfusion solutions in settings where stored blood is unavailable, impractical, or in short supply.

Differentiator

Problem solved

Functional benefit

Products and services

  • ErythroMer ErythroMer is a dried, bio-inspired artificial red blood cell designed to treat life-threatening blood loss when stored red blood cells are unavailable, undesirable, or in short supply. It is a nano-encapsulated human hemoglobin that mimics natural RBC physiology, can be freeze-dried for long-term storage at ambient conditions, and reconstituted in under two minutes for transfusion.

Quantifiable outcome

  • Every minute of delay in replacing lost blood increases mortality by 5%
  • +3 more outcomes

Companies that use Kalocyte

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Kalocyte technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Kalocyte partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core, major and minor.

  • ChryseacoreStrategic or Co-development Partner · 1 October 2025Exclusive licensing agreement for biosynthetic hemoglobin production. Global partnership combining Chryseas synthetic biology expertise with KaloCytes artificial red blood cell technology for medical emergency care.
  • Blue Knight (BARDA/Johnson & Johnson Innovation)majorStrategic or Co-development Partner · 28 January 2025Strategic collaboration between Biomedical Advanced Research and Development Authority (BARDA) and Johnson & Johnson JLABS. Blue Knight supports early-stage innovation in health security technologies. KaloCyte selected as Blue Knight company and awarded $250K QuickFire Challenge.
  • University of Maryland, Baltimore (UMB)coreStrategic or Co-development Partner · 31 January 2023Collaboration with UMB researchers led by Dr. Allan Doctor for ErythroMer development. KaloCyte is part of DARPA FSHARP consortium led by UMB School of Medicine. Company is UM BioPark affiliate with labs in UM School of Medicine's Center for Blood Oxygen Transport and Hemostasis (CBOTH).
  • University of Maryland BioParkcoreStrategic or Co-development PartnerKaloCyte is a UM BioPark Affiliate, located at Connect Labs at 4MLK. Provides access to research facilities, startup support resources, and Maryland biotech ecosystem.
  • University of PittsburghminorStrategic or Co-development PartnerCo-founder Dr. Phil Spinella is Professor at University of Pittsburgh and co-directs Trauma and Transfusion Medicine Research Center. Collaboration on transfusion medicine research and DARPA programs.
  • Penn State UniversityminorStrategic or Co-development PartnerCo-founder Dr. Dipanjan Pan is Dorothy Foehr Huck & J. Lloyd Huck Chair Professor in Nanomedicine at Penn State University. Co-invented ErythroMer with UMB team.
  • BioGeneratorminorStrategic or Co-development PartnerLeveraged BioGenerator's Grants, Fundamentals, and Grants-2-Business programs to craft and implement technical differentiation, accelerating regulatory path, and Federal de-risking grants strategies.

Scale indicators7 records

Recent moves8 records

Expansion highlights6 records

Kalocyte competitors and assessment

Company assessment

Direct peers

  • Haima Therapeutics: Haima Therapeutics is a Cleveland-based pre-clinical biotech developing synthetic and cryopreserved platelet products for trauma and surgical bleeding. It is the closest direct peer to KaloCyte, sharing the DARPA FSHARP consortium and a focus on shelf-stable blood product substitutes for hemorrhage control.
  • Velico Medical: Velico Medical is developing spray-dried plasma and other dried, shelf-stable blood products for pre-hospital and battlefield use. It directly overlaps KaloCyte's mission of fieldable, cold-chain-free transfusion therapeutics and targets the same end customers.
  • Prolong Pharmaceuticals: Prolong Pharmaceuticals is developing PEGylated hemoglobin-based oxygen carriers (SANGUINATE) for sickle cell disease and other indications. It is a direct competitor in the hemoglobin-based oxygen carrier (HBOC) therapeutic space that ErythroMer is also pursuing.

Broad incumbents

  • HbO2 Therapeutics: HbO2 Therapeutics (a subsidiary of OPKO Health) holds and develops hemoglobin-based oxygen carrier platforms, including the legacy Biopure/Hemopure program. It is a broad incumbent in the HBOC category and competes for the same regulatory and clinical milestones KaloCyte targets.
  • CSL Behring: CSL Behring is a global leader in plasma-derived and recombinant blood product therapies. As a broad incumbent in transfusion medicine, it represents both a potential competitor and a likely strategic-acquirer counterpart for KaloCyte's blood substitute franchise.
  • Baxter International: Baxter is a major global manufacturer of blood storage, processing and intravenous fluid products used in transfusion and trauma care. It operates broadly in the same end markets (hospitals, trauma centers, EMS) that KaloCyte plans to serve with ErythroMer.
  • Octapharma: Octapharma is one of the world's largest plasma product manufacturers, producing coagulation factors, immunoglobulins, and blood volume replacement products used in trauma and surgery. It is a broad incumbent serving the same hospital and emergency medicine channels targeted by ErythroMer.

Others

  • Cerus Corporation: Cerus develops INTERCEPT pathogen-reduction systems for platelets, plasma, and red blood cells. It is an adjacent enabling technology provider in the transfusion medicine ecosystem rather than a direct blood substitute competitor.
  • Terumo BCT: Terumo BCT manufactures blood collection, processing, and storage devices, and is developing pathogen-reduced and cryopreserved blood products. It is an adjacent supplier/infrastructure peer that supports the broader transfusion ecosystem in which ErythroMer would compete.
  • New York Blood Center: New York Blood Center is both a major blood bank operator and the venture investor that has backed KaloCyte (via NYBC Ventures). It is an ecosystem participant/strategic investor rather than a direct product competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Kalocyte social profiles

Digital presence

Kalocyte financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kalocyte leadership team

Management profile

Number of profiles

Profiles21 records

Kalocyte funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kalocyte M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kalocyte

What does Kalocyte do?

Kalocyte is a pre-clinical stage biotech company developing ErythroMer, a dried, bio-inspired artificial red blood cell substitute for emergency transfusion. ErythroMer is a nano-encapsulated human hemoglobin in a soft lipid nanoparticle shell that mimics native RBC physiology, can be freeze-dried for long-term ambient storage, and is reconstituted for transfusion in under two minutes. It is designed for use when stored red blood cells are unavailable, undesirable, or in short supply.

Is Kalocyte a public or private company?

Kalocyte is a private company. It is classified as venture growth investor backed and is currently operating.

When was Kalocyte founded?

Kalocyte was founded in 2016. It employs 11 to 50 people.

Where is Kalocyte based?

Kalocyte is headquartered in Baltimore, United States, in the North America region.

How does Kalocyte make money?

Three revenue lines are on record. Grant Funding is the primary driver. The others are investor Funding and pharmaceutical Product Sales (Future).

Who are Kalocyte's main competitors?

Direct peers on record are Haima Therapeutics, Velico Medical and Prolong Pharmaceuticals. Broad incumbents are HbO2 Therapeutics, CSL Behring, Baxter International and Octapharma. Others are Cerus Corporation, Terumo BCT and New York Blood Center.

Does Kalocyte have an API?

No public API is recorded for Kalocyte.

What industry is Kalocyte in?

Kalocyte's product category is Blood Substitute Pharmaceuticals. Its primary akta.pro industry code is HLAAAAAK, Therapeutic Enzymes & Enzyme Replacement Therapies (ERT). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
NewsDipanjan Pan named Huck director for innovation and entrepreneurship ecosystemsPenn State’s Huck Institutes of the Life Sciences has appointed Dipanjan Pan as its first director for innovation and entrepreneurship ecosystems to help researchers commercialize their discoveries. This appointment establishes a formalized pipeline for scaling research, funding, and intellectual property management, building on previous informal entrepreneurship initiatives. Pan brings extensive experience from founding multiple biotech companies, including KaloCyte, Innsight Tech, and Vitruvian Bio.The Times of IndiaWhat is shelf-stable synthetic blood? The scientific advancement that could transform battlefield and emergency care - The Economic TimesBiotech firm Kalocyte, in collaboration with researchers at the University of Maryland, Baltimore, has developed shelf-stable synthetic blood that can be freeze-dried into a powder, stored for years at room temperature, and reconstituted for transfusion in under two minutes. Funded by DARPA over more than 12 years of research, the product addresses the critical 'cold chain' problem that has prevented blood transfusions at the point of injury on battlefields and in remote emergencies. The project has met nearly all preclinical benchmarks and is entering the final program phase prior to human trials.openPR.comArtificial Blood Market to Reach USD 8.64 Billion by 2033 at 8.7% CAGR, Driven by Rising Demand for Blood Substitutes and Emergency Care SolutionsThe global artificial blood market reached USD 4,444.3 million in 2025 and is projected to grow to USD 8,648.0 million by 2033 at a compound annual growth rate of 8.7%, driven by increasing demand for blood substitutes and advancements in oxygen carrier technologies such as hemoglobin-based oxygen carriers and perfluorocarbon-based products. Market growth is fueled by rising trauma cases, the growing prevalence of chronic diseases, expanding surgical procedures, and the need for emergency care solutions where compatible donor blood is unavailable. Key companies including Hemarina, KaloCyte Inc., Grifols S.A., and others are expanding their artificial blood pipelines and focusing on commercialization of next-generation oxygen therapeutics, with applications spanning trauma care, military medicine, and surgical settings.BiobuzzBaltimore’s KaloCyte Partners on $46M DARPA Program to Develop Synthetic Blood ProductKaloCyte, a Baltimore-based company, partnered with DARPA for a $46M program to develop a synthetic blood substitute. Its product ErythroMer is a freeze-dried red blood cell substitute expected to enter in-human testing within two years. The company is also in a Series A financing round to support IND-enabling studies.GlobeNewswireScorpius Holdings Announces Collaboration with KaloCyte to Advance Manufacturing for ErythroMer™Scorpius Holdings announced a collaboration with KaloCyte to enhance manufacturing for ErythroMer, a dried artificial red blood cell. The companies are evaluating a commercial-scale manufacturing agreement. KaloCyte seeks Series A financing for IND-enabling studies and Phase 1 trials.Business & FinancialArtificial Blood Research Gets $46M Pentagon FundingThe U.S. Department of Defense granted $46.4 million to DARPA for artificial blood research, focusing on KaloCyte's ErythroMer. The freeze-dried product aims to mimic natural blood's oxygen delivery and clotting, with testing planned in simulations and animal models. Future clinical trials are needed to confirm safety and effectiveness.BioSpaceKaloCyte Closes Investment from New York Blood CenterKaloCyte closed an investment from New York Blood Center to support scale-up ahead of human trials. The company will raise a Series A equity round expected to close by late 2022, funding IND-enabling studies and Phase 1 trials.The Daily RecordWhy KaloCyte picked Baltimore and the BioPark - Maryland Daily RecordKaloCyte moved to Baltimore from St. Louis last month, citing the University of Maryland BioPark and proximity to stakeholders as key reasons. The company, developing artificial red blood cells, has $800,000 in seed funding and $5 million in grants, with plans to reach human trials in two-three years.The Daily RecordKaloCyte relocates to Baltimore’s UM BioPark - Maryland Daily RecordKaloCyte, a biotech developing a synthetic red blood cell substitute, relocated to Baltimore's UM BioPark. Its ErythroMer product has passed proof-of-concept and is in preclinical testing, with human trials expected within two to three years. The company expects to grow from two to five employees by end of 2019.PR NewswireKaloCyte Relocates to Downtown Baltimore as Co-Founders Join University of Maryland FacultyKaloCyte, a preclinical-stage healthcare biotechnology company, has relocated from St. Louis to Baltimore and become a University of Maryland BioPark affiliate, with its co-founders joining UM faculty and a new Center for Blood Oxygen Transport & Hemostasis (CBOTH) established at UMSOM to support the company's ErythroMer development. The company's synthetic red blood cell substitute can be freeze-dried for long-term storage and is the only product of its kind in development with this capability, with human trials expected within two to three years. KaloCyte currently has two full-time employees in Baltimore and expects to grow to five by the end of 2019, supported by nearly $6 million in federal awards and investor funding.